News & Updates

Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.

Treatment with vibegron significantly improves overactive bladder (OAB) symptoms in men who are being treated for benign prostatic hyperplasia (BPH), including daily micturitions and urgency episodes, results from the phase III COURAGE trial have shown. It is well tolerated and has an acceptable safety profile, with adverse event (AE) rates similar to placebo.

Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.